.RESEARCH HIGHLIGHT.06 August 2024.
A large randomized measured trial with cisgender women highlights the challenges of fidelity to a regular oral preexposure prophylaxis program and shows that twice-yearly injection of lenacapavir can easily sustain helpful HIV deterrence levels over 6 months.